Skip to main content

Advertisement

Table 2 Baseline cancer demographics

From: Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors

  Cases (n = 101) Controls (n = 201) P value
Single agent vs. combined
 Combination 28 (28) 14 (7) < 0.001
 Monotherapy 73 (72) 177 (93) < 0.001
Combined ICI
 Ipilimumab (anti-CTLA4) + nivolumab (anti-PD1) 24 (24) 13 (6) < 0.001
 Ipilimumab (anti-CTLA4) + pembrolizumab (anti-PD1) 1 (1) 0 0.33
 Tremelimumab (anti-CTLA4) + avelumab (anti-PD1) 1 (1) 0 0.33
 Tremelimumab (anti-CTLA4) + durvalumab (anti-PD1) 2 (2) 1 (0) 0.26
Monotherapy ICIa
 Pembrolizumab (anti-PD1) 35 (35) 62 (31) 0.50
 Nivolumab (anti-PD1) 25 (25) 85 (42) 0.003
 Ipilimumab (anti-CTLA4) 6 (6) 28 (14) 0.04
 Tremelimumab (anti-CTLA4) 1 (1) 0 0.33
 Atezolizumab (anti-PDL1) 6 (6) 2 (1) 0.02
 Avelumab (anti-PDL1) 0 0 1.00
 Durvalumab (anti-PDL1) 0 0 1.00
Overall types of ICI
 Any anti-PD1 85 (84) 160 (80) 0.34
 Any anti-CTLA4 35 (35) 42 (21) 0.01
 Any anti-PDL1 9 (9) 3 (1) 0.003
Days of follow-up [IQR] 175 [89,363] 290 [139,543] < 0.001
Other immune side effects during treatmentb
 No other immune side effects 51 (50) 86 (43) 0.20
 Hypophysitis/pituitary/adrenal 6 (6) 14 (7) 0.74
 Pneumonitis 30 (30) 24 (12) < 0.001
 Hepatitis 8 (8) 11 (5) 0.41
 Colitis 9 (9) 27 (13) 0.25
 Dermatitis 6 (6) 5 (2) 0.19
 Neurological 11 (11) 4 (2) 0.001
 Gastritis 3 (3) 5 (2) 1.00
  1. Values are n (%) or mean ± SD. All cases with ICI-associated myocarditis had ICI permanently discontinued. aIf most recent ICI therapy was monotherapy. bMore than one immune side effect may occur. Anti-CTLA4 anti-cytotoxic T-lymphocyte-associated protein 4, anti-PD1 anti-programmed cell death protein 1, anti-PDL1 anti-programmed death-ligand 1, ICI immune checkpoint inhibitors